Lutetium PSMA is administered via a drip and travels through the bloodstream seeking out prostate cancer cells before hitting them with targeted internal radiation, the University Hospitals Sussex NHS ...

Pre-treatment prostate MRI predicts recurrence and survival after surgery. Discover how imaging improves risk assessment.

Drugs used for prostate cancer may not increase bleeding or clotting risks when used with blood thinners, thus providing ...

Cribriform-positive prostate cancer outcomes needs to be further risk stratified to identify patients at high risk for metastasis.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one agent shown to shrink tumors in patients whose disease had resisted every ...

An ultrasound-based treatment for prostate cancer showed better safety and operative metrics versus robotic radical prostatectomy in an early analysis of a first-ever randomized trial. After 6 months ...

Detailed price information for Edap Tms Sa ADR (EDAP-Q) from The Globe and Mail including charting and trades.

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with histologic variants of prostate cancer. Perioperative outcomes from a randomized controlled trial ...

BOSTON, Feb. 27, 2026 /PRNewswire/ -- Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) ...